ACHIEVE Imaging Study Discontinued

WHITEHOUSE STATION, N.J., May 21, 2008 - Merck & Co., Inc. today announced the discontinuation of ACHIEVE (An Assessment of Coronary Health Using an Intima-Media Thickness Endpoint for Vascular Effects), an imaging study evaluating MK-0524A (ER niacin/laropiprant) in patients with Heterozygous... [read full story]                    

Add Comment
There are also 59 related articles
View all news articles about*:
*Newstin tag cloud displays all featured persons, associated organisations, related topics, regions and companies